An observational study in Leishmaniasis, sponsored by Knight Therapeutics (USA) Inc. Withdrawn at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-08-28.
Sponsored by Knight Therapeutics (USA) Inc · Observational
This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine (Impavido) in the US and who weigh > 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
Objective: The purpose of this observational study is to fulfill PMR 2127-4 for the miltefosine NDA (204684): implement a higher-weight-patient registry for the time period Mar 2015-Mar 2020.
Study Design: This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with Impavido in the US and who weigh > 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
Population: Leishmaniasis patients treated with Impavido who weigh more than 75 kg.
Drug Product:
Drug name: Impavido (50 mg capsules). Dosing regimen: as per the Impavido Product Label
Study Procedures: Patients who weigh more than 75 kg will become aware of the Impavido Higher-Weight Patient Registry via the Impavido website. By calling 1-866-588-5405, the patient will be connected to the Impavido Higher-Weight Patient Registry Coordinating Center. A trained staff member will acquaint the patient with the goals and procedures of the study. If the patient tentatively agrees to participate in the study over the telephone, the patient will be mailed information forms, the Consent/Assent Forms, and the Consent for the patient's physician to release medical information. Receipt of the two signed Consent and/or Assent Forms by the Coordinating Center will signify patient consent. The Coordinating Center will contact the patient's physician at the end of treatment, and at 1, 3, and 6 months after completing treatment, to collect data on efficacy and adverse effects (only during treatment).
Sample Size and Study Duration: Estimated 3-10 patients per year for 5 years.
Outcome Parameters:
Efficacy Adverse effects
Analysis: Baseline data, compliance to prescribed treatment, and outcomes will be reported for individual patients and for all patients.
leishmaniasis patients who are administered miltefosine
Exclusion Criteria:
[none]
Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed \>75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
Drug: Miltefosine
miltefosine: target 2.5 mg/kg/day for 28 days
Also known as: Impavido
Number of patients cured
Determination of possible relationship of lower mg/kg daily doses of miltefosine and efficacy
Time frame: 6 months
Number of patients with adverse effects
Adverse events including symptoms and laboratory parameters (if available)
Time frame: 6 months
Documents are hosted by the registry — open the source record to download them.
This study is withdrawn, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Knight Therapeutics (USA) Inc